Application Code :
762-0122-0001
Created Date : Saturday, December 25, 2021-10:27 10:27:47Update Date : Saturday, January 8, 2022-11:37 11:37:42
IP Address : 194.225.214.29Submit Date : Saturday, January 8, 2022-11:37 11:37:49Email : sh_eskandarieh@yahoo.com
International Congress Form (for Faculty Members)
The Congress Reporting
 The congress reporting
After your trip: please fill out this page in English & press the Submit bottom1
|
|
Please give a briefing of your own observations and outcomes of the congress : |
To obtain complete and quality information, we need an MS patient information registration system |
|
Your observations and outcomes : |
The collective outcome debate focused on improving the quality of patient care during the Covid-19 epidemic for decreasing patient’s disability. Although robust data to support evidence-based recommendations on COVID-19 vaccinations is not yet available, this practice guideline in MENACTRIMS 2021 aim was to offer guidance on vaccinating MS patients during the COVID-19 pandemic based on previous vaccine studies, mechanism of action of each Disease Modifying Therapy, currently available COVID-19 vaccine studies, and expert opinion. A group of regional experts selected by MENACTRIMS (Middle East North Africa Committee for Treatment and Research in Multiple Sclerosis) held two consecutive meetings and several subsequent discussions to review all available evidence regarding COVID-19 vaccines in MS patients. The aim was to develop practical recommendations that would support clinical practice in the region. After reviewing all of the evidence, preliminary recommendations were developed by a subcommittee. Using the Delphi methodology through online meetings, the final version of this guideline was developed. COVID-19 vaccination is recommended for all MS patients, and currently available vaccines are safe and effective. Attenuated but potentially partially protective vaccine response is expected in MS patients taking S1P modulators and B cell-depleting therapies. Other DMTs are not expected to significantly impact efficacy of COVID-19 vaccines. Coordinating vaccine timing with dosing regimens for some therapies may optimize vaccine efficacy. |
|
Please upload your poster or first page of your oral presentation : |
http://gsia.tums.ac.ir/images/UserFiles/55874/Forms/762/Poster-1021.pdf |